Trial Condition(s):

Contraception, Heavy menstrual bleeding

Induction of CYP3A4 by rifampin

Bayer Identifier:

91392

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2004-002617-36

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
16
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Natazia/Qlaira (EV/DNG, BAY86-5027)
Accepts Healthy Volunteers
N/A

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Bayer Pharma AG

Berlin, Germany, 13353

Status
Completed
 

For details, please refer to trial results

Additional Information